- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03319121
The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-cardiac chest pain (NCCP) is very common in the general population but symptom alone or patient's characteristics do not adequately differentiate cardiac and esophageal cause. Cardiologists are usually consulted first to exclude life-threatening acute coronary syndrome. Tests that are performed to exclude ischemic heart disease include exercise stress test and the more invasive coronary angiography. A negative stress test or angiogram or the presence of mild blockage of a single vessel disease will usually be adequate to exclude significant ischemia as a cause for chest pain.
The next most important cause of unexplained chest pain would be gastro-esophageal reflux disease (GERD). GERD and its complications of Barrett's oesophagus and oesophageal adenocarcinoma have increased markedly in recent decades, not just in the developed countries but also in Asia. Although relatively less common among populations in Malaysia, there are data to suggest an increasing prevalence of reflux disease largely a result of obesity and increased intra-abdominal pressure.
Dexlansoprazole (Takeda Pharmaceuticals, Japan) is a novel dual delayed release system recently approved by the FDA for treatment of heartburn associated with non-erosive and erosive reflux disease. It is unknown if dexlansoprazole is effective as an empirical therapy for NCCP.
Another approach would be therapy guided by investigations including high resolution (HR) esophageal impedance manometry and 24-hour pH-impedance studies. Study of esophageal function has greatly evolved with the recent availability of high resolution multi-channel solid state manometer and impedance. Water swallows are commonly used in esophageal manometric studies to evaluate for peristaltic abnormalities. Esophageal pH monitoring does not detect all gastroesophageal reflux (GER) events but with the combination of impedance, this technique allows detection of GER of gas and acid or non-acid liquids. These tests would enable diagnosis of GERD and functional chest pain and thereby allow targeted therapy.
For treatment of GERD, dexlansoprazole is effective and for functional chest pain, nonspecific adenosine antagonist, theophylline is proven to improve symptoms in patient with hypersensitive esophagus. A selective serotonin reuptake inhibitor (SSRI) is also effective for functional chest pain , however it is not known if theophylline is more effective than any other SSRIs.It is unknown about the response rates based on the guided therapy approach compared to the empirical PPI therapy.
Therefore, the aim of the intervention is to evaluate the effectiveness of empirical therapy vs. guided therapy on symptoms unexplained non-cardiac chest pain.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Kelantan
-
Kubang Kerian, Kelantan, Malaysia, 16150
- Hospitial Universiti Sains Malaysia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Participants with chest pain but normal angiogram or a negative stress test or normal electrocardiogram and cardiac enzyme.
Exclusion Criteria:
- Participants with any medications that might affect the upper GI tract, previous surgeries of the upper GI tract and a negative endoscopic examination for peptic ulcer disease and upper GI tract malignancies
- Participants with chronic, debilitating or life-threatening medical conditions and presence of overt psychiatric or psychological disturbances.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empirical therapy group
Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
|
Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
Other Names:
|
Experimental: Guided therapy group
Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
|
Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-cardiac chest pain symptoms assessed by visual analog scale (VAS)
Time Frame: 8 weeks
|
Visual analog scale (VAS) was used to assess the non-cardiac chest pain symptoms.
VAS is a psychometric response scale.
The scale has scores from 0 to 10 with 1 cm interval between scores and with 0 denotes no pain, 5 denote moderate pain and 10 denote the worst possible pain.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-cardiac chest pain symptoms assessed by gastroesophageal reflux disease questionnaire (GERDQ)
Time Frame: 8 weeks
|
Gastroesophageal reflux disease questionnaire (GERDQ) was used to assess the non-cardiac chest pain symptoms.
GERDQ is a 6-item questionnaire developed for the diagnosis of GERD in a primary care setting.
The total score of 0-8 is interpreted as less likely GERD and total score 9-18 is highly suggestive of GERD.
|
8 weeks
|
Non-cardiac chest pain symptoms assessed by quality of life in reflux and dyspepsia questionnaire (QOLRAD)
Time Frame: 8 weeks
|
Quality of life in reflux and dyspepsia questionnaire (QOLRAD) was used to assess the non-cardiac chest pain symptoms.
QOLRAD is a disease-specific questionnaire including 25 items combined into 5 dimensions: emotional distress, sleep disturbances, vitality, food/drinks problem and physical/social functioning.
A seven-point graded Likert scale is used to rate the QOLRAD.
Lower scores indicate a more severe impact on daily life and vice versa.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yeong Yeh Lee, MD, PhD, Universiti Sains Malaysia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Chest Pain
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Gastrointestinal Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Dexlansoprazole
- Lansoprazole
- Theophylline
Other Study ID Numbers
- 14070265
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Cardiac Chest Pain
-
Clinical Locomotion ScienceOdense University Hospital; University of Southern Denmark; The County of Funen... and other collaboratorsCompletedUndiagnosed Chest Pain | Musculoskeletal Chest Pain | Non-cardiac Chest PainDenmark
-
Linkoeping UniversityOstergotland County Council, SwedenActive, not recruitingCardiac Anxiety | Non-cardiac Chest PainSweden
-
Linkoeping UniversityRecruitingCardiac Anxiety | Non-cardiac Chest PainSweden
-
Chinese University of Hong KongTerminatedNon-Cardiac Chest PainChina
-
Clinical Locomotion ScienceOdense University Hospital; University of Southern Denmark; The County of Funen... and other collaboratorsCompletedIschemic Heart Disease | Non-Cardiac Chest Pain | Undiagnosed Chest Pain | Musculoskeletal Chest PainDenmark
-
Cairo UniversityActive, not recruitingNonspecific Cardiac Chest PainEgypt
-
Brigham and Women's HospitalCompletedGastroesophageal Reflux Disease | Non-Cardiac Chest Pain
-
Chinese University of Hong KongTerminated
-
CHRISTUS HealthCompletedChest Pain | Cardiac EventUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminatedFunctional Chest PainNetherlands
Clinical Trials on Empirical therapy group
-
Princess Margaret Hospital, Hong KongMedtronicWithdrawnHeart Failure | Cardiac Resynchronization Therapy | EchocardiographyChina
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Yonsei UniversityRecruitingAtrial FibrillationKorea, Republic of
-
Yonsei UniversityRecruitingParoxysmal Atrial FibrillationKorea, Republic of
-
Peking Union Medical College HospitalUnknownHyperglycemia | Critical Illness | Respiratory FailureChina
-
Fundación Pública Andaluza para la gestión de la...Completed
-
Huashan HospitalMedtronicRecruiting
-
Rigshospitalet, DenmarkNot yet recruitingCardiac Implantable Electronic Device Infection
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Abramson Cancer Center of the University of PennsylvaniaCompletedAcute Myeloid Leukemia | AMLUnited States